TD Cowen provided a buy rating on GRAIL shares on August 6, 2026.
4 reports, 2 independent
Updated Fri 00:00
No new developments lately
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen provided a buy rating on GRAIL shares on August 6, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.RBC assumed coverage and Morgan Stanley increased target price for GRAIL.1 source
TD Cowen issues a buy rating for GRAIL.1 source
Keep exploring
The entities involved
-
GRAIL
American biotechnology and pharmaceutical company
-
TD Cowen
American investment bank
- Multiple financial firms, including TD Cowen, Goldman Sachs, and Mizuho, issued various rating changes and price target updates across several stocks.
- TD Cowen provided analyst ratings and price targets for Werner Enterprises, while Citigroup also lifted its price target based on company performance.
Related events
- TD Cowen raised its price target and issued a buy rating for Globe Life.
- TD Cowen restated a 'buy' rating on Affiliated Managers Group (AMG) on June 6, 2026.
- TD Cowen issued a buy rating and price target for Dexcom on October 9, 2026.
- TD Cowen upgraded the stock rating for Generac on October 6, 2026.
- TD Cowen lifted its price target and gave a buy rating for Hilton Worldwide.